Affiliate disclosure: This article contains affiliate links. If you buy through them, we may earn a commission at no extra cost to you. This does not influence our assessment of the evidence below.
Evidence rating: Moderate — the oral probiotic strains have published trials, though mounting evidence for long-term plaque reduction is narrower than the marketing implies
What DentaBiome Claims To Be
DentaBiome is a dissolvable oral tablet containing probiotic strains marketed for gum and tooth health. The pitch is that the right bacteria in the mouth can outcompete pathogens and reduce plaque, gum inflammation, and bleeding.
The microbiome idea is sound — dysbiotic oral microbiota is associated with periodontitis and gingivitis. The question, as always, is whether a probiotic tablet delivering a few bacteria can measurably shift that ecology.
What’s Actually In It
DentaBiome lists four probiotic strains, no CFU amounts disclosed:
- Lactobacillus paracasei
- Lactobacillus reuteri
- Bacillus subtilis
- Bacillus coagulans
Each has published evidence, though the strength varies.
What The Research Shows
According to PubMed:
L. reuteri reduced bleeding and gum inflammation in multiple trials. A meta-analysis of 8 randomized controlled trials in people with gingivitis or periodontitis found that Lactobacillus reuteri supplementation significantly reduced bleeding on probing (pooled standardized difference 0.43) and reduced CPITN (Community Periodontal Index of Treatment Needs) scores, suggesting measurable periodontal improvement. The effect was independent of mechanical cleaning, meaning the probiotic added something beyond regular brushing. DOI
L. paracasei improved markers in a 12-week trial. A randomized, double-blind, placebo-controlled study in 40 people with mild-to-moderate periodontitis given Lactobacillus paracasei for 12 weeks found significant reductions in plaque index, bleeding on probing, and pocket depth versus placebo. No adverse events. DOI
Bacillus subtilis shows benefit in one trial, caution in another. A randomized controlled study in 60 adults with gingivitis given Bacillus subtilis for 30 days found reductions in gingival inflammation and plaque compared to placebo. However, Bacillus species can form spores and persist in the mouth; long-term safety monitoring is limited, and guidelines do not formally recommend routine Bacillus consumption. DOI
No published long-term data exists. The trials above run 8–12 weeks. Nothing published tracks oral probiotic use beyond that timeframe or tests for persistence of the introduced strains or shifts in the wider oral microbiota after discontinuation.
The Honest Verdict
What holds up: Lactobacillus reuteri and L. paracasei have randomized trials showing modest but measurable reductions in bleeding and inflammation. Bacillus subtilis has one positive trial. These are real bacteria with published evidence in oral outcomes.
What doesn’t: The trials are short, the dosing in DentaBiome is undisclosed, and the long-term persistence or ecological effect of introduced strains is unknown. An oral probiotic cannot replace flossing, brushing, and professional cleaning. Marketing often overstates the plaque-fighting power — the effect observed is real but incremental.
Who this makes sense for: Someone with mild gingivitis who brushes and flosses regularly and wants an evidence-plausible addition. Someone at risk for periodontal disease due to family history or systemic inflammation.
Who should skip it: Anyone with advanced periodontitis who needs professional intervention. Anyone with immunocompromise or indwelling catheters should discuss probiotics with their doctor first.
Check current pricing and availability
View DentaBiome on the official site
This article is for informational purposes only and is not medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration. Talk to your physician or dentist before starting any supplement.
Research cited via PubMed: